{
    "Trade/Device Name(s)": [
        "Libre Rio Continuous Glucose Monitoring System"
    ],
    "Submitter Information": "Abbott Diabetes Care, Inc.",
    "510(k) Number": "K233861",
    "Predicate Device Reference 510(k) Number(s)": [
        "K222447"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "SBH"
    ],
    "Summary Letter Date": "June 7, 2024",
    "Summary Letter Received Date": "December 6, 2023",
    "Submission Date": "December 5, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1355"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Libre Rio Sensor",
        "Libre Rio App"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement",
        "Glucose oxidase chemical reaction",
        "Bluetooth Low Energy (BLE)",
        "Near Field Communication (NFC)"
    ],
    "Methodologies": [
        "Continuous glucose monitoring",
        "Electrochemical detection"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "App",
        "Mobile application",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for Abbott Libre Rio integrated continuous glucose monitoring system for over-the-counter use in non-insulin using adults, utilizing a sensor and mobile app for real-time glucose monitoring.",
    "Indications for Use Summary": "Over-the-counter integrated continuous glucose monitoring system indicated for non-insulin using persons age 18 and older to detect trends and track patterns of euglycemia, hyperglycemia, and hypoglycemia, with autonomous digital communication capability.",
    "fda_folder": "Clinical Chemistry"
}